AOC-3 Inhibitor
Non-Proliferative Diabetic Retinopathy
Phase 2Active
Key Facts
About Vantage Biosciences
Vantage Biosciences is a private, clinical-stage biotech developing an oral AOC-3 inhibitor for inflammatory conditions, with a primary focus on non-proliferative diabetic retinopathy (NPDR). The company is preparing to advance its lead candidate into a Phase 2 clinical trial and is based in London. Its strategy involves intervening early in disease biology to provide disease-modifying therapy, and it is actively seeking collaborations to expand its network and team.
View full company profileTherapeutic Areas
Other Non-Proliferative Diabetic Retinopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| AXPAXLI (OTX-TKI) | Ocular Therapeutix | Phase 3 |